Vital Signs - The Analyst's Perspective - March 2015 Issue

USD 500.00

* Required Fields

USD 500.00


Be the first to review this product

This issue of Vital Signs, released on April 3, 2015, discusses next-generation sequencing bioinformatics partnerships, FDA approval of Novartis's ZARXIO, 23andMe's foray into drug development, and Johnson & Johnson's sale of Cordis to Cardinal Health.

Table of Contents

Vital Signs - The Analyst's Perspective - March 2015 IssueVital Signs - March 2015 IssueThis week's issue

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.